ALLO-501A is a gene-modified cell therapy commercialized by Allogene Therapeutics, with a leading Phase II program in Diffuse Large B-Cell Lymphoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ALLO-501A’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ALLO-501A is expected to reach an annual total of $633 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ALLO-501A Overview

ALLO-501A is under development for the treatment of diffuse large B-cell Lymphoma, marginal zone B-cell Lymphoma, primary mediastinal B-cell Lymphoma and follicular lymphoma. The drug candidate is an anti-CD19 Allogeneic CAR T (AlloCAR T) therapy in which a T cell receptor gene is knocked out to avoid GvHD and the CD52 gene is knocked out to render the drug resistant to anti-CD52 antibody treatment which can be used to suppress the host immune system.

Allogene Therapeutics Overview

Allogene Therapeutics is a clinical stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$38.5 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$255.8 million in FY2021, compared to an operating loss of US$258.2 million in FY2020. The net loss of the company was US$257 million in FY2021, compared to a net loss of US$250.2 million in FY2020.

For a complete picture of ALLO-501A’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.